Fresenius raises €1B in dual-tranche bond sale

What's the deal? German healthcare group Fresenius has issued €1 billion in bonds, split evenly across two tranches maturing in 2031 and 2034.

The €500 million 2031 notes carry a 3.375% coupon; the €500 million 2034 notes pay 3.750%. Settlement is expected July 8, 2026.

Fresenius will use the proceeds for general corporate purposes, including refinancing existing debt. It has applied to list the bonds on the Luxembourg Stock ExchangeDealroom has a profile for this one. Try Dealroom →.

Why now? The sale fully covers Fresenius' refinancing needs for 2026 while tackling some debt maturities due in 2027.

It also extends the average maturity of the company's debt and does not change its full-year 2026 guidance.

What could go wrong? Fresenius is committed to a target leverage corridor of 2.5 to 3.0x net debt/EBITDA. Missing that range would undercut its deleveraging push.

Fixed-rate coupons above 3% also lock in higher borrowing costs should rates fall.

The signal: The dual-tranche bond sale reflects a broader move by late-stage healthcare groups to lock in fixed-rate funding early and cut refinancing risk. For Fresenius — whose businesses include Fresenius KabiDealroom has a profile for this one. Try Dealroom →, a specialist in lifesaving infusion and clinical nutrition medicines — a stronger balance sheet is central to its #FutureFresenius deleveraging push, following its recent sale of a Fresenius Medical CareDealroom has a profile for this one. Try Dealroom → stake for $1.15 billion.

Read more: The Wall Street Journal

Image credit: Generated with Gemini